CZ276295A3 - Immune nanoparticles carrying anti-cd-4 monoclonal antibodies and the use thereof for prophylaxis and/or treating pathologic states caused by infection with hiv viruses or as biological reaction substances - Google Patents
Immune nanoparticles carrying anti-cd-4 monoclonal antibodies and the use thereof for prophylaxis and/or treating pathologic states caused by infection with hiv viruses or as biological reaction substances Download PDFInfo
- Publication number
- CZ276295A3 CZ276295A3 CZ952762A CZ276295A CZ276295A3 CZ 276295 A3 CZ276295 A3 CZ 276295A3 CZ 952762 A CZ952762 A CZ 952762A CZ 276295 A CZ276295 A CZ 276295A CZ 276295 A3 CZ276295 A3 CZ 276295A3
- Authority
- CZ
- Czechia
- Prior art keywords
- antibodies
- nanoparticles
- monoclonal antibodies
- infection
- prophylaxis
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 43
- 208000015181 infectious disease Diseases 0.000 title abstract description 6
- 230000001575 pathological effect Effects 0.000 title description 6
- 238000011321 prophylaxis Methods 0.000 title description 6
- 241000700605 Viruses Species 0.000 title description 2
- 239000000126 substance Substances 0.000 title description 2
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- -1 methyliden malonate compound Chemical class 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 3
- 239000000376 reactant Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000017960 syncytium formation Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XJDDLMJULQGRLU-UHFFFAOYSA-N 1,3-dioxane-4,6-dione Chemical compound O=C1CC(=O)OCO1 XJDDLMJULQGRLU-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 108010083930 HIV Receptors Proteins 0.000 description 1
- 102000006481 HIV Receptors Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XDZLHTBOHLGGCJ-UHFFFAOYSA-N hexyl 2-cyanoprop-2-enoate Chemical compound CCCCCCOC(=O)C(=C)C#N XDZLHTBOHLGGCJ-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003124 immunolabeling method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9304750A FR2704227B1 (fr) | 1993-04-22 | 1993-04-22 | Immunonanoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues a une infection par le virus hiv. |
| US10170093A | 1993-08-04 | 1993-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ276295A3 true CZ276295A3 (en) | 1996-06-12 |
Family
ID=26230266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ952762A CZ276295A3 (en) | 1993-04-22 | 1994-04-22 | Immune nanoparticles carrying anti-cd-4 monoclonal antibodies and the use thereof for prophylaxis and/or treating pathologic states caused by infection with hiv viruses or as biological reaction substances |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0695312A1 (fr) |
| JP (1) | JPH08512287A (fr) |
| CN (1) | CN1121725A (fr) |
| AU (1) | AU6681494A (fr) |
| CA (1) | CA2160983A1 (fr) |
| CZ (1) | CZ276295A3 (fr) |
| FI (1) | FI954827A0 (fr) |
| HU (1) | HUT73392A (fr) |
| SK (1) | SK130395A3 (fr) |
| WO (1) | WO1994024168A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722411B1 (fr) * | 1994-07-18 | 1996-10-04 | Union Pharma Scient Appl | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv |
| JP4611561B2 (ja) * | 2000-04-12 | 2011-01-12 | Ｄｉｃ株式会社 | 新規なビニル系樹脂およびその製造方法 |
| GB2381792B (en) * | 2000-04-12 | 2004-08-04 | Dainippon Ink & Chemicals | Antifouling coating composituion |
| JP3961312B2 (ja) | 2002-02-26 | 2007-08-22 | 株式会社デンソー | 内燃機関の制御装置 |
| CN102649818B (zh) * | 2011-02-25 | 2014-10-08 | 厦门大学 | 抗cd4蛋白的单克隆抗体及其活性片段及用途 |
| CN110903394B (zh) * | 2019-12-27 | 2021-09-07 | 源道隆（苏州）医学科技有限公司 | 可结合cd4的多肽及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0329184A3 (fr) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimères et conjugaison antimère |
-
1994
- 1994-04-22 CN CN94191869A patent/CN1121725A/zh active Pending
- 1994-04-22 SK SK1303-95A patent/SK130395A3/sk unknown
- 1994-04-22 CA CA002160983A patent/CA2160983A1/fr not_active Abandoned
- 1994-04-22 EP EP94914433A patent/EP0695312A1/fr not_active Ceased
- 1994-04-22 WO PCT/FR1994/000459 patent/WO1994024168A1/fr not_active Application Discontinuation
- 1994-04-22 HU HU9503028A patent/HUT73392A/hu unknown
- 1994-04-22 CZ CZ952762A patent/CZ276295A3/cs unknown
- 1994-04-22 JP JP6522857A patent/JPH08512287A/ja active Pending
- 1994-04-22 AU AU66814/94A patent/AU6681494A/en not_active Abandoned
-
1995
- 1995-10-11 FI FI954827A patent/FI954827A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9503028D0 (en) | 1995-12-28 |
| AU6681494A (en) | 1994-11-08 |
| FI954827A (fi) | 1995-10-11 |
| SK130395A3 (en) | 1996-06-05 |
| HUT73392A (en) | 1996-07-29 |
| JPH08512287A (ja) | 1996-12-24 |
| WO1994024168A1 (fr) | 1994-10-27 |
| EP0695312A1 (fr) | 1996-02-07 |
| FI954827A0 (fi) | 1995-10-11 |
| CN1121725A (zh) | 1996-05-01 |
| CA2160983A1 (fr) | 1994-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2277995C (fr) | Composition et procede permettant de reguler l'adherence de cellules et de biomolecules a des surfaces hydrophobes | |
| Arneborn et al. | T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella | |
| Dubois-Dalcq et al. | Protein A-peroxidase: a valluable tool for the localization of antigens. | |
| Rabellino et al. | Receptors for C3 and IgG on macrophage, neutrophil and eosinophil colony cells grown in vitro | |
| JP4680361B2 (ja) | 分離・回収方法 | |
| Krishnaraj et al. | Age-associated alterations in human natural killer cells: 2. Increased frequency of selective NK subsets | |
| CZ276295A3 (en) | Immune nanoparticles carrying anti-cd-4 monoclonal antibodies and the use thereof for prophylaxis and/or treating pathologic states caused by infection with hiv viruses or as biological reaction substances | |
| AU2543797A (en) | Methods for measurement of lymphocyte function | |
| JPH05504882A (ja) | ヒト末梢血液単核細胞のアミノ酸アミド処理によるｌａｋ細胞活性化増強 | |
| HAMMERSTRØM | Human adherent mononuclear blood cells: Cytolytic and cytostatic activity and characterization of effector cells during in vitro culture | |
| FR2722411A1 (fr) | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv | |
| Denner et al. | Suppression of human lymphocyte mitogen response by retroviruses of type D: I. Action of highly purified intact and disrupted virus | |
| CA2348780A1 (fr) | Peptides d'ezrine de regulation/a deploiement | |
| Wåhlin et al. | Enumeration andCharacterization of Human Killer and Natural Killer Cells by a Modified Single‐Cell Assay | |
| Barth et al. | Brief communication: Agglutination of 2, 4-dinitrophenyl-tagged normal human leukocytes by concanavalin A: Possible relationship to their ability to evoke production of leukemia-associated antibodies | |
| US20020076732A1 (en) | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide | |
| FR2704227A1 (fr) | Immunonanoparticules porteuses d'anticorps monoclonaux anti-CD4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues à une infection par le virus HIV. | |
| EP4196790A1 (fr) | Procédé de séparation et/ou de détection et/ou de quantification in vitro de composés infectieux dans un matériel biologique | |
| Singh et al. | Immune-complexes-mediated evasion of Plasmodium knowlesi from destruction by macrophages | |
| Slavin | In vitro release of histamine from human peripheral leukocytes with compound 48/80 | |
| Morgan Jr | Studies on the antibodies and the role of complement in autologous humoral cytotoxicity to human neoplasms | |
| Valpotić et al. | T and B lymphocytes in horses persistently infected with equine infectious anaemia virus | |
| Moore | Nature of In Situ Host Anti-Tumour Immune Responses | |
| FR2673429A1 (fr) | Inhibiteur lymphocytaire des fonctions du systeme immunitaire. |